RMSL RemSleep Holdings

REMSleep Patent Application Has Been Allowed by the United States Patent and Trademark Office

REMSleep Patent Application Has Been Allowed by the United States Patent and Trademark Office

CLEARWATER, FL, Sept. 03, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL) announces that another utility patent for its Nasal Ventilation System has been allowed by the United States Patent and Trademark Office.  REMSleep will file the necessary paperwork to pay for issuance and, thereafter, REMSleep should be awarded a patent in approximately 8 weeks.  REMSleep will maintain a continuation application for adding any improvements and/or changes to the patent lineage.

REMSleep is now waiting on delivery of silicone raw materials from supply chain to produce inventory for market launch.  We are expecting materials to arrive to manufacturer approximately first week of October.  Production should be available a few days after and we will begin shipping samples to distributors, etc.  During this period, we are making all necessary preparations to be fully regulatory compliant with FDA for the launch of the Deltawave CPAP pillows interface.

Immediately after launch of the Deltawave REMSleep intends to submit 510K application for its next generation “Longevity”.  The Longevity CPAP pillows interface 510K application is expected to take approximately 5 months to clearance.  The “Longevity” design is complete, and no additional R&D is needed.  There will be a third generation CPAP interface mask to follow Longevity.  We expect to have the third-generation pillows mask to market by end of 2025.  We expect REMSleep to be a substantial company by end of 2025.

About REMSleep Holdings, Inc.

REMSleep Holdings, Inc. is a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients. Our focus is primarily designing and manufacturing devices and products for the treatment of sleep apnea and other respiratory conditions. With over 30 years of collective experience in CPAP therapy, the REMSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance. We diligently strive for our products to make a difference and improve the condition of those suffering from sleep apnea.

Forward-looking Statements

This press release may contain forward-looking statements regarding the Company. All statements, other than statements of historical fact included herein, are "forward-looking statements" including statements regarding the Company’s future prospects and risks in investing in Company’s common stock. These statements are based upon the Company's current expectations and speak only as of the date hereof. Financial performance in one period does not necessarily mean continued or better performance in the future. The Company's actual results in any endeavor may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, which factors or uncertainties may be beyond our ability to foresee or control. Other risk factors include the status of the Company's common stock as a "penny stock" and those risk factors stated in reports filed with the U.S. Securities and Exchange Commission or SEC on its EDGAR website (URL:)

Contact:

REMSleep Holdings, Inc.

14175 ICOT Blvd

Suite 300

Clearwater, FL 33760

Email:

Phone: 912-590-2001



EN
03/09/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RemSleep Holdings

 PRESS RELEASE

REMSleep Patent Application Has Been Allowed by the United States Pate...

REMSleep Patent Application Has Been Allowed by the United States Patent and Trademark Office CLEARWATER, FL, Sept. 03, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL) announces that another utility patent for its Nasal Ventilation System has been allowed by the United States Patent and Trademark Office.  REMSleep will file the necessary paperwork to pay for issuance and, thereafter, REMSleep should be awarded a patent in approximately 8 weeks.  REMSleep will maintain a continuation application for adding any improvements and/or changes to the patent lineage. REMSleep is...

 PRESS RELEASE

REMSleep Holdings Inc. Issues Shareholder Letter

REMSleep Holdings Inc. Issues Shareholder Letter Company Unveils Internal Corporate Goal of Capturing 10% of the CPAP Mask Market Within 24 Months CLEARWATER, Fla., Aug. 06, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL), a leader in innovative sleep apnea products, published the following letter to shareholders. Dear REMSleep Shareholders and Interested Investors: Our company’s primary focus is two-fold. First, we are dedicated to providing high-quality products and experiences for CPAP therapy to support our customers and their families. Second, we are intensely ...

 PRESS RELEASE

REMSleep Holdings, Inc. Announces Distributor Request for DELTAWAVE Na...

REMSleep Holdings, Inc. Announces Distributor Request for DELTAWAVE Nasal Pillows System Samples CLEARWATER, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL), a leader in innovative sleep apnea products, is thrilled to announce that a significant distributor in the CPAP industry has requested samples of its new nasal interface, the DELTAWAVE Nasal Pillows System. This request marks a pivotal step in REMSleep's mission to revolutionize sleep apnea treatment with cutting-edge technology and superior comfort. REMSleep is currently in the process of preparing the...

 PRESS RELEASE

REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAV...

REMSleep Holdings Inc. Announces Strategic Marketing Plan for DELTAWAVE Nasal Pillows System CLEARWATER, Fla., July 17, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings Inc. (OTCQB: RMSL), a pioneer in sleep apnea treatment solutions, is thrilled to announce a comprehensive marketing strategy for its revolutionary DELTAWAVE Nasal Pillows System. This strategic plan aims to significantly expand the market presence of DELTAWAVE by identifying and partnering with key distributors nationwide The DELTAWAVE Nasal Pillows System, designed with cutting-edge technology, offers an innovative solution fo...

 PRESS RELEASE

REMSleep Holdings Inc. Receives 510(K) Clearance on Product

REMSleep Holdings Inc. Receives 510(K) Clearance on Product CLEARWATER, Fla., July 09, 2024 (GLOBE NEWSWIRE) -- REMSleep Holdings, Inc. (OTCQB: RMSL) announces the company has been awarded 510(K) Clearance for the new Deltawave CPAP Pillows Interface mask. The company would like to share the following correspondence with its shareholders: Re: K233415Trade/Device Name: DELTAWAVE Nasal Pillows SystemRegulation Number: 21 CFR 868.5905Regulation Name: Noncontinuous Ventilator (IPPB)Regulatory Class: Class IIProduct Code: BZDDated: October 4, 2023Received: October 10, 2023 Dear Judy Strzepek...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch